semaglutide banned Critics debate banning GLP-1 weight-loss medications in sports for their potential as performance enhancers. link in bio 🔗 Regulator acts to close loophole

This landmark study of over 17,000 adults with established cardiovascular disease and overweight or obesity without diabetes demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg compared to placebo

Patients should be advised to stay well hydrated, eat small frequent meals, and report severe or persistent gastrointestinal symptoms, as these may necessitate dose adjustment or additional management strategies

One you might expect, one you might not expect

Check your specific formulary through your Anthem member portal

This guide will provide an overview to help you make informed decisions